Who is eligible for clinical trial NCT02180711?

Participants must meet protocol criteria for Non Hodgkin Lymphoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02180711 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma (NCT02180711)

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Acerta Pharma BV

🩺 Plain-English Summary (8th-Grade Level)

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL

Who can join: Review the eligibility criteria below.

Location: Research Site — Tucson, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

Research Site — Tucson, Arizona
Research Site — Downey, California
Research Site — Duarte, California
Research Site — Fountain Valley, California
Research Site — Santa Monica, California
Research Site — Coral Gables FL, Florida
Research Site — Chicago, Illinois
Research Site — Chicago, Illinois
Research Site — Chicago, Illinois
Research Site — Louisville, Kentucky
Research Site — New Orleans, Louisiana
Research Site — Ann Arbor, Michigan
Research Site — Morristown, New Jersey
Research Site — Lake Success, New York
Research Site — New York, New York
Research Site — Columbus, Ohio
Research Site — Greenville, South Carolina
Research Site — Dallas, Texas
Research Site — Houston, Texas
Research Site — San Antonio, Texas
Research Site — Temple, Texas
Research Site — Salt Lake City, Utah
Research Site — Spokane, Washington
Research Site — Edmonton, Alberta
Research Site — London, Ontario

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non Hodgkin Lymphoma

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) — Duarte, California
TmCD19-IL18 in CD19+ Cancers — Philadelphia, Pennsylvania
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma — Cincinnati, Ohio
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas — Iowa City, Iowa
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies — Cleveland, Ohio

Explore by condition: All Non Hodgkin Lymphoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗